Literature DB >> 12658766

Telomerase activity in condyloma acuminatum tissue with different HPV types.

Yating Tu1, Shanjuan Chen, Chao Fan, Nengxing Lin, Houjun Liu, Zhixiang Liu.   

Abstract

The telomerase activity in condyloma acuminatum (CA) tissue with human papillomavirus (HPV) types of 6/11 and 16/18 was detected to investigate the function of telomerase in the occurrence, development and carcinogenesis of genital CA. Forty-two biopsies from patients with genital CA and 30 control tissue samples were tested for telomerase activity, HPV presence and types. The telomerase activity was determined by modified telomerase repeat amplification protocol (TRAP) assay and HPV typing by polymerase chain reaction (PCR) with typing-specific primers. Results showed that HPV-DNA was negative and the expression rate of telomerase was 16.7% in all normal skin samples. All CA samples were positive for HPV (6/11 type was found in 32 cases, 16/18 in 3 and mixed type in 7). Telomerase activity was detectable in all CA patients. The telomerase activity in CA of 16/18 type was apparently higher than in CA of 6/11 type. It was concluded that the hyperplasia in CA might be increased as a result of HPV infection, suggesting that the activation of telomerase by HPV, especially by 16/18 type may play a role in the etiology and carcinogenesis of genital CA.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12658766     DOI: 10.1007/BF02857686

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  9 in total

1.  The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats.

Authors:  G B Morin
Journal:  Cell       Date:  1989-11-03       Impact factor: 41.582

Review 2.  Activation of telomerase in a human tumor.

Authors:  T de Lange
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-12       Impact factor: 11.205

3.  Telomerase activity exclusively in cervical carcinomas and a subset of cervical intraepithelial neoplasia grade III lesions: strong association with elevated messenger RNA levels of its catalytic subunit and high-risk human papillomavirus DNA.

Authors:  P J Snijders; M van Duin; J M Walboomers; R D Steenbergen; E K Risse; T J Helmerhorst; R H Verheijen; C J Meijer
Journal:  Cancer Res       Date:  1998-09-01       Impact factor: 12.701

4.  Increased telomerase activity and decreased telomere length in genital condylomata acuminata.

Authors:  M A Rahat; N Lahat; A Sharon; H Gazawi; H Abramovici; J Bornstein
Journal:  Int J STD AIDS       Date:  1999-11       Impact factor: 1.359

5.  Transition of human papillomavirus type 16 and 18 transfected human foreskin keratinocytes towards immortality: activation of telomerase and allele losses at 3p, 10p, 11q and/or 18q.

Authors:  R D Steenbergen; J M Walboomers; C J Meijer; E M van der Raaij-Helmer; J N Parker; L T Chow; T R Broker; P J Snijders
Journal:  Oncogene       Date:  1996-09-19       Impact factor: 9.867

6.  Viral E6-E7 transcription in the basal layer of organotypic cultures without apparent p21cip1 protein precedes immortalization of human papillomavirus type 16- and 18-transfected human keratinocytes.

Authors:  R D Steenbergen; J N Parker; S Isern; P J Snijders; J M Walboomers; C J Meijer; T R Broker; L T Chow
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

7.  The RNA component of human telomerase.

Authors:  J Feng; W D Funk; S S Wang; S L Weinrich; A A Avilion; C P Chiu; R R Adams; E Chang; R C Allsopp; J Yu
Journal:  Science       Date:  1995-09-01       Impact factor: 47.728

8.  Telomerase activity in human ovarian carcinoma.

Authors:  C M Counter; H W Hirte; S Bacchetti; C B Harley
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-12       Impact factor: 11.205

9.  Specific association of human telomerase activity with immortal cells and cancer.

Authors:  N W Kim; M A Piatyszek; K R Prowse; C B Harley; M D West; P L Ho; G M Coviello; W E Wright; S L Weinrich; J W Shay
Journal:  Science       Date:  1994-12-23       Impact factor: 47.728

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.